Table 1 The summary of GEO datasets used in the present study
GEO accession | Number of samples | patients subgroup | Application in this study |
|---|---|---|---|
GSE28654 [7] | 89 | 61Â M-CLL and 28 U-CLL | WGCNA to reveal hub genes correlating with IGHV status |
GSE38611 [8] | 136 | 76Â M-CLL and 60 U-CLL | Validation for the correlation of hub gene expression with IGHV status |
GSE40570 [11] | 159 | 96Â M-CLL vs 63 U-CLL | Validation for the correlation of hub gene expression with IGHV status |
GSE51529 [9] | 229 | 131Â M-CLL and 85 U-CLL | Validation for the correlation of hub gene expression with IGHV status |
GSE69034 | 144 | 86Â M-CLL and 58 U-CLL | Validation for the correlation of hub gene expression with IGHV status |
GSE9992 [12] | 60 | 24Â M-CLL and 36 U-CLL | Validation for the correlation of hub gene expression with IGHV status |
GSE50006 | 210 | 188 CLL and 32 healthy donors | Validation for expression difference of hub genes between CLL and healthy dornors |
GSE32018 [23] | 127 | 17 CLL, 23 FL, 22 DLBCL, 24 MCL, 15 MALT-MZL, 13 NMZL and 13 normal lymphoid tissues | Validation for expression difference of hub genes between various type of lymphoid neoplasms |
GSE58211 [13] | 300 | 29 Binet stage A, 179 Binet stage B and 92 Binet stage C CLL patients | Validation for expression difference of hub genes between different stages of CLL |
GSE10138 [14] | 68 | 32 progressive and 36 stable CLL patients | Validation for the correlation of hub gene expression with treatment response in CLL patients |
GSE103265 | 19 | 8 CLL and 11 Richter syndrome | Validation for expression difference of hub genes between stable CLL and Richter syndrome patients |
GSE39671 [15] | 130 | 130 CLL | survival analysis of TTFT stratificated by hub gene expression |
GSE22762 [16] | 107 | 107 CLL | survival analysis of TTFT/OS stratificated by hub gene expression |